 MorphoSys AG NASDAQ: MOR and Human Immunology Biosciences, Inc. HIBio, a biotechnology company, have established an equity participation agreement and license agreements to allow HIBio to develop and commercialize MorphoSys felzartamab, an anti-CD38 antibody, and MOR210,. 